Transcenta Therapeutics granted EirGenix a non‑exclusive license to its highly intensified continuous bioprocessing (HiCB) platform, including continuous perfusion and hybrid continuous purification technology. The head of Transcenta, Xueming Qian, said the company expects upfront and milestone payments plus future royalties; EirGenix will deploy HiCB to support CDMO clients seeking intensified biologics manufacturing. GEN reported the agreement and quoted both CEOs. The deal reflects growing industry momentum to scale continuous biomanufacturing to lower costs and improve global access to biologics.